ClinicalTrials.gg
CompletedNCT01707290KONTINUEUpdated May 12, 2017Results posted

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

A Phase 3 interventional study of Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 38 sites in 4 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
125
Allocation
Non-randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.

Enrollment
25th of 84
125 · median 70
Started
2013
with 7 others
Phase 3
45 of 84
none open now
Registered
20th of 84
by date
Lead sponsor
74 of 84
Vertex Pharmaceuticals Incorporated

Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 25th largest by enrollment, is one of 8 that started in 2013, is one of 45 in phase 3, and was the 20th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ivacaftor

ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing ivacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety of long-term ivacaftor treatment in participants with cystic fibrosis (CF) from Studies 110 (NCT01614457), 111 (NCT01614470), and 113 (NCT01685801).

Read the detailed description

Ivacaftor is the first Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator to show an improvement in CFTR function and clinical benefit in participants with CF. Results from Phase 3 studies (NCT00909532 [Study 102] and NCT00909727 [Study 103]) showed that ivacaftor is effective in the treatment of participants with CF who have the G551D-CFTR mutation, as evidenced by sustained improvements in CFTR channel function (measured by reduction in sweat chloride concentration) and corresponding substantial, durable improvements in lung function, pulmonary exacerbations, respiratory symptoms, and weight gain. Ivacaftor was also well tolerated, as evidenced by the rates and reasons for premature discontinuation and results of safety assessments.

Ivacaftor (Trade Name Kalydeco; 150 mg tablets) was initially approved in the United States for the treatment of CF in participants 6 years of age and older who have a G551D mutation in the CFTR gene.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants from Study 110 or Study 111 entering the ivacaftor arm must have completed the assigned study drug treatment duration in the previous study.
  • Participants from Study 113 entering the ivacaftor arm must have completed all study related treatments through the Follow-up Visit and met the Study 113 responder criteria during the previous study.
  • Participants entering the observational arm must have completed at least 4 weeks of study drug treatment in their previous study (Study 110 or Study 111), must have completed the previous study but do not wish to enroll in the ivacaftor arm, or must have completed the previous study but do not meet the inclusion criteria of the ivacaftor arm.
  • Participants of entering the ivacaftor arm must not be pregnant.
  • Participants entering the ivacaftor arm must be willing to comply with requirements.

Exclusion criteria

Exclusion Criteria (Ivacaftor Arm Only):

  • History of any illness or condition that might confound the results of the study or pose an additional risk in administering ivacaftor to the Participant.
  • Use of moderate or strong inhibitors or inducers of cytochrome P450 (CYP) 3A.
  • Evidence of cataract or lens opacity at or before the Day 1 Visit.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Ivacaftor

    Participants who received Ivacaftor 150 milligram (mg) tablet and/or Placebo matched to Ivacaftor tablet orally, every 12 hours (q12h) in the previous study VX11-770-110 (Study 110; NCT01614457), VX12-770-111 (Study 111; NCT01614470) or VX12-770-113 (Study 113; NCT01685801); received Ivacaftor 150 mg tablet q12h in this VX12-770-112 (Study 112; NCT01707290) up to 104 weeks.

    Drug: Ivacaftor

  • No intervention
    Observational

    Participants who received Ivacaftor 150 mg tablet and/or Placebo matched to Ivacaftor tablet, orally, q12h in the previous Study 110 (NCT01614457) or Study 111 (NCT01614470), were observed (did not receive study drug) in this Study 112 (NCT01707290) for up to 2 years.

Interventions

  • 150 mg tablet, oral use, every 12 hours (q12h)

    Also known as: Kalydeco, VX-770

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) in Ivacaftor Arm

    AE: any untoward medical occurrence in a participants during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. TEAEs were defined as adverse events with start date or increased severity on and after the first dose of study drug through Week 108.

    Time frame: Day 1 up to Week 108 (Study 112)

Secondary outcomes

  1. Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 2, 12, 24, 36, 48, 60, 72, 84, 96, and 104

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 6 to 17 years and for female participants aged 6 to 15 years. Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.

    Time frame: Baseline, Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104 (Study 112)

  2. Absolute Change From Baseline in Body Mass Index (BMI) at Week 2,12, 24, 36, 48, 60, 72, 84, 96 and 104

    BMI was defined as weight in kg divided by height in m\^2. Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.

    Time frame: Baseline, Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104 (Study 112)

  3. Absolute Change From Baseline in Sweat Chloride at Week 2, 24, 48 and 104

    Sweat samples were collected using an approved collection device. Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.

    Time frame: Baseline, Week 2, 24, 48 and 104 (Study 112)

  4. Absolute Change From Baseline in Respiratory Domain of the Cystic Fibrosis Questionnaire Revised (CFQ-R) at Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104

    The CFQ-R is a validated participant reported outcome measuring health related quality of life for participants with CF. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health related quality of life. Baseline was defined as the most recent measurement before intake of the first dose of study drug (ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.

    Time frame: Baseline, Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104 (Study 112)

  5. Number of Pulmonary Exacerbations Events

    Pulmonary exacerbation events include those events which require treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events were reported. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.

    Time frame: Through Week 104 (Study 112)

  6. Number of Participants With Serious Adverse Events (SAEs) in Observational Arm

    SAE was defined as a medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.

    Time frame: up to 2 years (Study 112)

07

Results

Posted May 12, 2017

Participant flow

Participant flow — Overall Study
MilestoneIvacaftor ArmObservational Arm
Started1214
Completed353
Not completed861
Withdrew: Adverse event (ae)10
Withdrew: Physician decision10
Withdrew: Lost to follow-up30
Withdrew: Withdrawal of consent (not due to ae)40
Withdrew: Commercial drug available601
Withdrew: Other unspecified170

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) in Ivacaftor Arm

AE: any untoward medical occurrence in a participants during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. TEAEs were defined as adverse events with start date or increased severity on and after the first dose of study drug through Week 108.

Time frame:
Day 1 up to Week 108 (Study 112)
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) in Ivacaftor Arm
participantsIvacaftor Arm
Participants with TEAEs117
Participants with SAEs27
SecondaryAbsolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 2, 12, 24, 36, 48, 60, 72, 84, 96, and 104

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 6 to 17 years and for female participants aged 6 to 15 years. Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.

Time frame:
Baseline, Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104 (Study 112)
Reported as:
Mean · Percent predicted of FEV1
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 2, 12, 24, 36, 48, 60, 72, 84, 96, and 104
Percent predicted of FEV1Ivacaftor Arm: Study 110Ivacaftor Arm: Study 111Ivacaftor Arm: Study 113
Baseline71.8 ± 20.478.3 ± 21.162.8 ± 22.2
Change at Week 23.8 ± 84.4 ± 7.74 ± 7.2
Change at Week 125.4 ± 8.95.5 ± 8.34.9 ± 6.7
Change at Week 244.5 ± 8.47.1 ± 8.34.6 ± 8.5
Change at Week 364.4 ± 7.17.5 ± 8.24.9 ± 8.2
Change at Week 484.4 ± 7.56.4 ± 10.74.9 ± 9
Change at Week 604.5 ± 8.48.2 ± 8.34.5 ± 8.8
Change at Week 723.6 ± 8.97.8 ± 9.25.9 ± 9.2
Change at Week 845.4 ± 13.57.7 ± 7.64.8 ± 7.2
Change at Week 964.1 ± 14.69.9 ± 6.45.9 ± 8.1
Change at Week 1044.6 ± 13.24.9 ± 5.86.3 ± 10
SecondaryAbsolute Change From Baseline in Body Mass Index (BMI) at Week 2,12, 24, 36, 48, 60, 72, 84, 96 and 104

BMI was defined as weight in kg divided by height in m\^2. Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.

Time frame:
Baseline, Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104 (Study 112)
Reported as:
Mean · kilogram per square meter (kg/m^2)
Absolute Change From Baseline in Body Mass Index (BMI) at Week 2,12, 24, 36, 48, 60, 72, 84, 96 and 104
kilogram per square meter (kg/m^2)Ivacaftor Arm: Study 110Ivacaftor Arm: Study 111Ivacaftor Arm: Study 113
Baseline23.75 ± 5.6323.15 ± 5.2824.81 ± 5.76
Change at Week 20.06 ± 0.430.16 ± 0.470.07 ± 0.43
Change at Week 120.32 ± 0.590.39 ± 0.620.22 ± 0.6
Change at Week 240.43 ± 0.920.65 ± 0.960.17 ± 0.91
Change at Week 360.62 ± 1.040.64 ± 1.070.02 ± 1.27
Change at Week 480.54 ± 1.390.58 ± 1.220.28 ± 1.26
Change at Week 600.72 ± 1.320.25 ± 1.090.38 ± 1.22
Change at Week 721.05 ± 1.730.45 ± 1.340.22 ± 1.22
Change at Week 840.72 ± 1.510.33 ± 1.420.23 ± 0.92
Change at Week 960.49 ± 1.440.1 ± 1.490.52 ± 1.28
Change at Week 1040.42 ± 1.490.16 ± 1.370.88 ± 1.39
SecondaryAbsolute Change From Baseline in Sweat Chloride at Week 2, 24, 48 and 104

Sweat samples were collected using an approved collection device. Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.

Time frame:
Baseline, Week 2, 24, 48 and 104 (Study 112)
Reported as:
Mean · millimole per liter (mmol/L)
Absolute Change From Baseline in Sweat Chloride at Week 2, 24, 48 and 104
millimole per liter (mmol/L)Ivacaftor Arm: Study 110Ivacaftor Arm: Study 111Ivacaftor Arm: Study 113
Baseline60.9 ± 19.480.2 ± 22.855.7 ± 22.2
Change at Week 2-19.3 ± 10.7-38.4 ± 27.5-4.5 ± 10.9
Change at Week 24-13 ± 18.4-39.2 ± 271.1 ± 15.8
Change at Week 48-13.5 ± 16.2-40.6 ± 26.1-1.9 ± 17.8
Change at Week 104-13.7 ± 22.9-32.9 ± 26.85.4 ± 18.1
SecondaryAbsolute Change From Baseline in Respiratory Domain of the Cystic Fibrosis Questionnaire Revised (CFQ-R) at Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104

The CFQ-R is a validated participant reported outcome measuring health related quality of life for participants with CF. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health related quality of life. Baseline was defined as the most recent measurement before intake of the first dose of study drug (ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.

Time frame:
Baseline, Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104 (Study 112)
Reported as:
Mean · units on a scale
Absolute Change From Baseline in Respiratory Domain of the Cystic Fibrosis Questionnaire Revised (CFQ-R) at Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104
units on a scaleIvacaftor Arm: Study 110Ivacaftor Arm: Study 111Ivacaftor Arm: Study 113
Baseline68.6 ± 21.672.4 ± 20.365.9 ± 18.8
Change at Week 25.5 ± 17.94.5 ± 17.513.2 ± 16.2
Change at Week 1211.6 ± 185.7 ± 18.513.5 ± 20
Change at Week 246.7 ± 193.4 ± 18.78.5 ± 14.9
Change at Week 3612.1 ± 19.35.7 ± 13.87.9 ± 20.5
Change at Week 489.5 ± 17.64.4 ± 13.211.4 ± 15.7
Change at Week 607.1 ± 18.64.4 ± 10.98.6 ± 19.3
Change at Week 7210.4 ± 22.25.6 ± 11.88.6 ± 19
Change at Week 8410.5 ± 19.58.8 ± 14.14.9 ± 14.6
Change at Week 968.8 ± 21.10 ± 9.59.4 ± 14.7
Change at Week 1049.2 ± 141.9 ± 8.819.9 ± 16
SecondaryNumber of Pulmonary Exacerbations Events

Pulmonary exacerbation events include those events which require treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events were reported. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.

Time frame:
Through Week 104 (Study 112)
Reported as:
Number · pulmonary exacerbation events
Number of Pulmonary Exacerbations Events
pulmonary exacerbation eventsIvacaftor Arm: Study 110Ivacaftor Arm: Study 111Ivacaftor Arm: Study 113
Number of Pulmonary Exacerbations Events47306
SecondaryNumber of Participants With Serious Adverse Events (SAEs) in Observational Arm

SAE was defined as a medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.

Time frame:
up to 2 years (Study 112)
Reported as:
Number · participants
Number of Participants With Serious Adverse Events (SAEs) in Observational Arm
participantsObservational Arm
Number of Participants With Serious Adverse Events (SAEs) in Observational Arm1

Adverse events

Collected over Day 1 up to Week 108 for Ivacaftor arm; up to 2 years for Observational arm (Study 112). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ivacaftor Arm—27/121 (22.3%)117/121 (96.7%)
Observational Arm—1/4 (25%)—
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventIvacaftor ArmObservational Arm
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations21/1211/4
GastroenteritisInfections and infestations2/1210/4
PneumoniaInfections and infestations2/1210/4
Influenza A virus test positiveInvestigations1/1210/4
Cardiomyopathy acuteCardiac disorders1/1210/4
HaemoptysisRespiratory, thoracic and mediastinal disorders1/1210/4
Respiratory failureRespiratory, thoracic and mediastinal disorders1/1210/4
Crohn's diseaseGastrointestinal disorders1/1210/4
Abdominal painGastrointestinal disorders1/1210/4
FlatulenceGastrointestinal disorders1/1210/4
Most frequent other events
Showing 10 of 282
Most frequent other events
EventIvacaftor ArmObservational Arm
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations49/121—
CoughRespiratory, thoracic and mediastinal disorders41/121—
HeadacheNervous system disorders23/121—
Sinus congestionRespiratory, thoracic and mediastinal disorders22/121—
Sputum increasedRespiratory, thoracic and mediastinal disorders22/121—
NasopharyngitisInfections and infestations21/121—
Oropharyngeal painRespiratory, thoracic and mediastinal disorders18/121—
SinusitisInfections and infestations18/121—
PyrexiaGeneral disorders17/121—
Nasal congestionRespiratory, thoracic and mediastinal disorders17/121—

Baseline characteristics

Age, Customized
Age, Customized(participants)Ivacaftor ArmObservational ArmTotal
6 to 11 years21122
12 to 17 years11112
18 years and over89291
Sex: Female, Male
Sex: Female, Male(Participants)Ivacaftor ArmObservational ArmTotal
Female61364
Male60161
08

Study locations

38 sites
  • Birmingham, Alabama, United States
  • Palo Alto, California, United States
  • Denver, Colorado, United States
  • Hartford, Connecticut, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Iowa City, Iowa, United States
  • Lexington, Kentucky, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • Grand Rapids, Michigan, United States
  • Minneapolis, Minnesota, United States
  • St. Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • New York, New York, United States
  • Syracuse, New York, United States
  • Valhalla, New York, United States
  • Chapel Hill, North Carolina, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
  • Morgantown, West Virginia, United States
  • Madison, Wisconsin, United States
  • Leuven, Belgium
  • Montpellier, France
  • Paris, France
  • Belfast, United Kingdom
  • Edinburgh, United Kingdom
09

References and documents

Publications

  • Pilewski JM, De Boeck K, Nick JA, Tian S, DeSouza C, Higgins M, Moss RB. Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations. Pulm Ther. 2020 Dec;6(2):303-313. doi: 10.1007/s41030-020-00129-2. Epub 2020 Sep 23. PubMed 32965659 ↗
  • Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M; VX11-770-110 (KONDUCT) Study Group. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015 Jul;3(7):524-33. doi: 10.1016/S2213-2600(15)00201-5. Epub 2015 Jun 9. PubMed 26070913 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2012
First posted
Oct 16, 2012
Start
Feb 2013
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Results first posted
May 12, 2017
Last update
May 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01707290
Collaborators
Cystic Fibrosis Foundation
Responsible party
Sponsor
First posted
Oct 16, 2012
Start date
Feb 2013
Primary completion
Apr 2016
Completion
Apr 2016
Results posted
May 12, 2017
Last update
May 12, 2017

Study contacts

Joseph Pilewski, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivacaftor

Start the discussion